Precision Oncology Chief Medical Officer Gerald Messerschmidt sits down to talk with ASCO Post‘s Ronald Piana regarding the future of immunotherapy. Dr. Messerschmidt touches on a number of topics, including immune surveillance, checkpoint inhibitors, cancer cell cloaking and the future of therapy combinations.

To read the complete article, please click here.